| |
| |
|
| Insider
Information: |
Gilman Steven C |
| Relationship: |
|
| City: |
Lexington |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
142,930 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$682,189 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
142,930 |
|
|
| Total
Value |
$682,189 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 9.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Director |
2018-12-12 |
0 |
2016-05-26 |
0 |
Premium* |
|
|
Contrafect Corp |
CFRX |
CEO, Director |
2017-07-25 |
20,800 |
2016-07-27 |
0 |
Premium* |
|
|
Momenta Pharmaceuticals Inc |
MNTA |
Director |
2020-10-01 |
0 |
2018-06-20 |
0 |
Premium* |
|
|
Vericel Corp |
VCEL |
|
2024-05-01 |
11,000 |
2018-09-04 |
0 |
Premium* |
|
|
Akebia Therapeutics, Inc. |
AKBA |
|
2023-06-06 |
87,130 |
2018-12-12 |
0 |
Premium* |
|
|
Scynexis Inc |
SCYX |
|
2023-06-15 |
24,000 |
2020-12-21 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
48 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VCEL |
Vericel Corp |
|
– • – |
2018-09-04 |
4 |
OE |
$2.63 |
$23,670 |
D/D |
9,000 |
9,000 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Director |
– • – |
2016-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
Director |
– • – |
2018-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
10,231 |
10,231 |
0 |
- |
|
| VCEL |
Vericel Corp |
|
• • – |
2024-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,200 |
11,000 |
0 |
- |
|
| SCYX |
Scynexis Inc |
Director |
– • – |
2022-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
14,000 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Director |
– • – |
2018-06-11 |
4 |
AS |
$5.12 |
$6,830 |
D/D |
(1,334) |
17,333 |
0 |
- |
|
| MNTA |
Momenta Pharmaceuticals I... |
Director |
– • – |
2020-07-22 |
4 |
A |
$10.63 |
$106,300 |
D/D |
10,000 |
17,796 |
0 |
- |
|
| MNTA |
Momenta Pharmaceuticals I... |
Director |
– • – |
2020-07-29 |
4 |
OE |
$10.63 |
$106,300 |
D/D |
10,000 |
17,796 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Director |
– • – |
2018-05-29 |
4 |
AS |
$5.22 |
$6,958 |
D/D |
(1,333) |
18,667 |
0 |
- |
|
| CFRX |
Contrafect Corp |
CEO |
• • – |
2016-07-27 |
4 |
B |
$2.48 |
$49,600 |
D/D |
20,000 |
20,000 |
2.81 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Director |
– • – |
2017-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,000 |
0 |
- |
|
| MNTA |
Momenta Pharmaceuticals I... |
Director |
– • – |
2020-08-05 |
4 |
OE |
$10.63 |
$138,190 |
D/D |
13,000 |
20,796 |
0 |
- |
|
| CFRX |
Contrafect Corp |
CEO |
• • – |
2017-07-25 |
4 |
B |
$1.24 |
$992 |
D/D |
800 |
20,800 |
2.73 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
|
– • – |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,700 |
23,931 |
0 |
- |
|
| SCYX |
Scynexis Inc |
|
• • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
24,000 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Director |
– • – |
2018-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
27,333 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
|
– • – |
2019-11-20 |
4 |
B |
$3.43 |
$19,894 |
D/D |
5,800 |
29,731 |
0.01 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
|
– • – |
2020-06-08 |
4 |
AS |
$12.08 |
$55,169 |
D/D |
(4,567) |
38,864 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
|
– • – |
2022-06-03 |
4 |
AS |
$0.36 |
$1,653 |
D/D |
(4,567) |
43,430 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
|
– • – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
13,700 |
43,431 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
|
– • – |
2021-06-07 |
4 |
AS |
$3.32 |
$15,163 |
D/D |
(4,567) |
47,997 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
|
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
13,700 |
52,564 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
|
– • – |
2023-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
87,130 |
0 |
- |
|
48 Records found
|
|
Page 2 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
